Lisata Therapeutics Completes Patient Enrollment in Phase 1b/2a CENDIFOX Trial for Certepetide in Advanced Solid Tumors
Lisata Therapeutics announces completion of patient enrollment in the CENDIFOX trial for certepetide in advanced solid tumors.Quiver AI SummaryLisata Therapeutics, Inc. has announced the successful completion...
Lisata Therapeutics Named 'Specialized BioTherapeutics Company of the Year' at 2024 BioTech Breakthrough Awards
Lisata Therapeutics receives the ‘Specialized BioTherapeutics Company of the Year’ award for innovative cancer therapies and clinical advancements.Quiver AI SummaryLisata Therapeutics, Inc., a clinical-stage...
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
Esperion Therapeutics, Inc. ESPR incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred a...